Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro

Full text
Leis-Filho, Antonio Fernando [1] ; de Faria Lainetti, Patricia [2] ; Emiko Kobayashi, Priscila [1] ; Fonseca-Alves, Carlos Eduardo [2, 3] ; Laufer-Amorim, Renee [1]
Total Authors: 5
[1] Sao Paulo State Univ UNESP, Dept Vet Clin, BR-18618681 Botucatu, SP - Brazil
[2] Sao Paulo State Univ UNESP, Dept Vet Surg & Anim Reprod, BR-18618681 Botucatu, SP - Brazil
[3] Paulista Univ UNIP, Inst Hlth Sci, BR-17048290 Bauru, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: PHARMACEUTICS; v. 13, n. 6 JUN 2021.
Web of Science Citations: 0

HER2 is a prognostic and predictive marker widely used in breast cancer. Lapatinib is a tyrosine kinase inhibitor that works by blocking the phosphorylation of the receptor HER2. Its use is related to relatively good results in the treatment of women with HER2+ breast cancer. Thus, this study aimed to verify the effects of lapatinib on four canine primary mammary gland carcinoma cell cultures and two paired metastatic cell cultures. Cultures were treated with lapatinib at concentrations of 100, 500, 1000 and 3000 nM for 24 h and the 50% inhibitory concentration (IC50) for each cell culture was determined. In addition, a transwell assay was performed to assess the ability of lapatinib to inhibit cell migration. Furthermore, we verified HER2 expression by RT-qPCR analysis of cell cultures and formalin-fixed paraffin-embedded tissues from samples corresponding to those used in cell culture. Lapatinib was able to inhibit cell proliferation in all cell cultures, but it was not able to inhibit migration in all cell cultures. The higher the expression of HER2 in a culture, the more sensitive the culture was to treatment. This relationship may be an indication that the expression of HER2 may be a predictive factor and opens a new perspective for the treatment of primary and metastatic mammary gland cancer. (AU)

FAPESP's process: 18/14041-4 - Lapatinib effects on Her2+ and Her2- canine mammary carcinoma cells cultured in vitro
Grantee:Antonio Fernando Leis Filho
Support type: Scholarships in Brazil - Master